"Conquest Research is partnering with physician practices throughout Central Florida to offer clinical trial opportunities to patients. We're conquering tomorrow's health conditions with today's research."

During the past decade, Conquest Research conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 2 clinical trials were completed, i.e. on average, 7.1% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 2 clinical trials were completed. i.e. 7.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Conquest Research" #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "Annovis Bio Inc." with 2 trials sponsored, "Biohaven Pharmaceuticals, Inc." with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Satsuma Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Conquest Research" #1 collaborator was "MCRA" with 1 trials as a collaborator, "Parexel" with 1 trials as a collaborator, "Premier Research Group plc" with 1 trials as a collaborator, "Prothena Biosciences Limited" with 1 trials as a collaborator and "TFS Trial Form Support" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Conquest Research" are "Alzheimer Disease" (9 trials), "Chronic Gout" (2 trials), "Migraine" (2 trials), "Migraine With Aura" (2 trials) and "Migraine Without Aura" (2 trials). Many other conditions were trialed in "Conquest Research" in a lesser frequency.

Most popular intervention types in "Conquest Research" are "Drug" (25 trials), "Other" (4 trials), "Biological" (2 trials), "Behavioral" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Donanemab" (3 trials), "Dihydroergotamine" (2 trials), "SEL-212A" (2 trials) and "SEL-212B" (2 trials). Other intervention names were less common.

The vast majority of trials in "Conquest Research" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Conquest Research". undefined are not yet recruiting, 11 are recruiting, 9 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 5 completed trials in Conquest Research, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Conquest Research, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".